H.B. Fuller: We Upgrade to Overweight from Neutral
H.B. Fuller is splitting from its cyclical peers — the market sees volume decline, but misses the earnings power from cost cuts and a high-margin acquisition. EBITDA is growing 9% YoY in 2Q:F26 even as volumes contract 4-6%, and EPS is on track for 13% growth in F2026.
Institutional-grade analysis used by equity desks before repricing events. 20 pages.
Report fact snapshot
- Publisher
- JPMorgan
- Date
- 2026-06-26
- Type
- Company Report
- Region
- United States
- Companies
- JPMorgan, Target, Fuller, Prior
- Key signal
- 8x
The market assumes H.B. Fuller is a low-growth cyclical with no earnings power in a flat-to-negative volume environment.
Adjusted EBITDA grew 9% in 2Q:F26 and EPS is forecast to rise 13% in F2026 to $4.80, driven by price increases, currency, and cost savings.
The market is undervaluing H.B. Fuller's self-help earnings trajectory and the strategic value of the AMS acquisition.
Based on JPMorgan research, June 2026 data and regional breakdowns
Key Signals
H.B. Fuller is growing earnings despite declining volumes, but the market prices it as a pure cyclical.
EBITDA grew 9% in 2Q:F26 while volumes declined 4-6%; EPS expected to rise 13% in F2026.
Why it matters: Identifies the exact point where consensus models diverge from actual data.
AMS acquisition and Quantum Leap savings provide near-term earnings catalysts.
AMS acquisition at 15.4x EBITDA (9.8x post-synergy); Quantum Leap adds $15m in F2026.
Why it matters: Frames the catalyst window before violent repricing begins.
H.B. Fuller is structurally winning through cost transformation and portfolio upgrade.
Quantum Leap cost savings of $10m in F2025, $15m in F2026, $25m in F2027; AMS acquisition adds high-margin medical adhesives.
Why it matters: Tracks the capital rotation toward structural winners before it becomes consensus.
What You Gain From This Report
Decision Insight
The mispricing reveals that H.B. Fuller's earnings power is structurally higher than the market prices.
Missed Risk
Failing to act means missing a re-rating as Quantum Leap and AMS synergies compound.
Timing Advantage
Acting now captures the catalyst window before earnings beats and synergy announcements force consensus to revise.
What you miss without the full report:
- Company-level positioning and stock picks
- Valuation assumptions and model inputs
- Price target logic and catalyst timeline
Why Institutional Investors Care
Consensus models price H.B. Fuller as a pure cyclical, missing the structural earnings lift from Quantum Leap and the AMS acquisition.
Capital should rotate from commoditized chemical names to specialty transformers with self-help earnings trajectories.
The 2Q:F26 earnings beat and AMS deal closing in the coming months provide a defined catalyst window for re-rating.
Report Summary
The market treats H.B. Fuller as a pure cyclical chemical company, assuming earnings will weaken with declining volumes. But the reality is that the company is growing earnings through price increases, currency tailwinds, and cost cuts, even as volumes contract. This disconnect between market perception and actual earnings power creates a re-rating opportunity.
Institutional Content Below
Full company-level breakdown, valuation assumptions, price target logic, and broker charts are locked in the full report.
Key Takeaways
- Earnings Growth Decoupled from Volumes: H.B. Fuller's adjusted EBITDA grew 9% in 2Q:F26 while volumes declined 4-6%, demonstrating earnings power independent of the volume cycle.
- Valuation Discount Signals Mispricing: H.B. Fuller trades at ~8x EBITDA while paying 15.4x for AMS (9.8x post-synergy), implying the market does not credit its own earnings quality.
- Quantum Leap Cost Savings Accelerating: The company will extract an additional $15m in costs in F2026 and $25m in F2027, steadily improving margins and supporting earnings growth.
- AMS Acquisition Opens High-Margin Growth: The $942m acquisition of Advanced Medical Solutions provides a structural growth pathway into higher-margin medical adhesives.
- 13% EPS Growth Validates Earnings Upgrade Cycle: F2026 EPS is forecast to rise to $4.80 from $4.24, representing 13% growth driven by price, currency, and cost savings, not volume recovery.
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the JPMorgan H.B. Fuller report. It helps users review H.B. Fuller: We Upgrade to Overweight from Neutral coverage, key takeaways, and related broker or sector research paths across consumer, H.B., Fuller:; JPMorgan, Target.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.
Request Full PDF Access
Get access to the full broker report, including company-level details, valuation assumptions, charts, and price target logic.
Access is provided through VIP service or request confirmation.